Neogen Chemicals: No Deviation in Utilization of ₹161 Crore Preferential Issue Funds
Neogen Chemicals Limited confirms no deviation in the utilization of ₹161 crore raised via preferential issue. Funds were allocated to subsidiary investment (₹100 crore), working capital (₹21 crore), and general corporate purposes (₹40 crore). All funds were utilized as planned, as per the Monitoring Agency Report by CRISIL Ratings.
This announcement is a routine compliance report regarding the utilization of funds from a past preferential issue. While it confirms proper fund usage, it does not introduce new material business developments or financial performance indicators that would significantly impact the company's valuation or investor sentiment.
The company has confirmed that there has been no deviation in the utilization of funds raised through the preferential issue, which is a positive indicator of financial discipline and adherence to stated objectives.
Neogen Chemicals Limited has reported that there has been no deviation or variation in the utilization of funds raised through its preferential issue of equity shares. The statement of deviation or variation for the quarter ended June 30, 2026, was reviewed by the Audit Committee on July 24, 2026.
The company raised ₹161 crore through a preferential issue of equity shares on April 18, 2026. The funds were allocated to three main purposes: ₹100 crore for investment in wholly-owned subsidiaries (Neogen Ionics Limited), ₹21 crore for working capital requirements, and ₹40 crore for general corporate purposes. The entire amount has been utilized as per the original plan.
Specifically, the ₹100 crore allocated for investment was utilized for capital expenditure related to the Pakhanjan project. This involved Neogen Chemicals subscribing to Compulsorily Convertible Debentures (CCDs) issued by Neogen Ionics Limited, which then subscribed to a rights issue of Neogen Morita New Materials Limited. These funds were ultimately remitted to Neogen Ionics Limited as an advance payment for the acquisition of its salt business, and then utilized for equipment purchase, civil work, and fabrication for the Pakhanjan project.
The ₹21 crore for working capital requirements was used to adjust the cash credit facility maintained with the State Bank of India. The ₹40 crore for general corporate purposes was also utilized towards the adjustment of the cash credit facility. CRISIL Ratings Limited, appointed as the monitoring agency, has issued its final report confirming the same, indicating no deviation in the utilization of the proceeds.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.